Key Takeaways REGN posted Q2 EPS of $12.89, up 12% year over year and beating the $8.03 consensus estimate.Q2 revenues rose 4% to $3.7B, driven by Eylea HD demand and higher Dupixent collaboration profits.Both Libtayo and Eylea HD sales topped estimates; Dupixent sales rose 22% to $4.3B globally.Regeneron Pharmaceuticals, Inc. ((REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which comfortably beat the Zacks Consensus Estimate of $8.03. The bottom line increased 12% from $11. ...